SSRI Efficacy in Excoriation (Skin-Picking) Disorder
Excoriation disorder shares OCD's DSM-5 chapter and its first-line drug class, but not, it turns out, anything close to OCD's SSRI response rate — a genuine gap between shared classification and shared pharmacology.
N.J., a 29-year-old man, is a software developer who works remotely and has recently started keeping his camera off during video meetings, citing "connection issues" that aren't real. He lives alone and has no significant medical history beyond mild eczema, managed with an over-the-counter moisturizer.
His skin-picking began in his early twenties, focused on his forearms and, more recently, his face, escalating over the past six months during a stretch of high work stress following a product launch. He picks for up to two hours daily, often without full awareness he's begun, and has developed visible scarring on both forearms and, more recently, on his jawline that he's started covering with makeup before video calls — the reason for the camera-off habit he hasn't disclosed to his team. His SPS-R today is 21, and this is his first psychiatric evaluation; he was referred by his dermatologist after presenting for the scarring itself.
Excoriation disorder shares its DSM-5 chapter with OCD and trichotillomania, and SSRIs remain the most commonly reasoned-toward first pharmacologic choice largely by classification analogy — but the actual controlled-trial evidence for SSRI efficacy in excoriation disorder specifically is thin and inconsistent, meaningfully weaker than OCD's own robust response rates, and closer in shape to trichotillomania's disappointing record than to OCD's. A few smaller trials show a modest signal; several others don't separate from placebo at all. N-acetylcysteine has a similar mixed-but-real evidence profile here as it does in trichotillomania, given the mechanistic and phenomenological overlap between the two body-focused repetitive behaviors. The honest starting point for this conversation isn't which drug to pick — it's being clear with him that "OCD-spectrum" doesn't mean "OCD-level drug response," for either option.
Sharing a chapter, not sharing a response rate
I want to name the actual evidence gap to him directly before we choose anything: excoriation disorder's SSRI trials are genuinely weaker and more inconsistent than what OCD patients see, closer to trichotillomania's disappointing record than to OCD's. If we start an SSRI, it should be framed as a reasonable, low-risk trial worth attempting, not as a near-certain fix the way it might be for a straightforward OCD referral.
Agreed, and I'd put N-acetylcysteine on equal footing in that conversation rather than as a fallback if the SSRI fails — its mixed trial evidence here is genuinely comparable to the SSRI's, not clearly weaker, given the phenomenological and likely mechanistic overlap with trichotillomania. He should be choosing between two honestly modest options, not a strong first-line drug and a backup supplement.
Whichever he picks, cognitive-behavioral therapy adapted for body-focused repetitive behaviors has more consistent evidence than either pharmacologic option and shouldn't get relegated to an afterthought because a medication decision is the more familiar conversation to have first. I'd refer for that today regardless of which drug, if any, he chooses to start alongside it.
Agreed: both the SSRI and N-acetylcysteine were presented to him as honestly comparable, modest-evidence options rather than a clear first choice and a backup, and he was given time to decide which to start rather than being steered toward either. A referral for CBT adapted to body-focused repetitive behaviors was placed today regardless of his medication decision.
No disagreement recorded among the three voices — the discussion converged on presenting both pharmacologic options with equal, honest uncertainty rather than resolving to a single recommendation.